SEC FORM 4

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

KPCB PBD Associates, LLC

(Last)

(First)

(Middle)

C/O KLEINER PERKINS CAUFIELD & BYERS

2750 SAND HILL ROAD

(Street)

MENLO PARK

94025

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Trius Therapeutics Inc [ TRSX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

Director	X	10% Owner
Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/06/2010

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	08/06/2010		C⁽¹⁾		1,055,581⁽³⁾	A	⁽¹⁾	1,055,581⁽³⁾	I	Shares are held directly by KPCB Pandemic and Bio Defense Fund, LLC⁽³⁾
Common Stock	08/06/2010		C⁽¹⁾		6,279⁽³⁾	A	⁽¹⁾	1,061,860⁽³⁾	I	Shares are held directly by KPCB PBD Founders Fund, LLC⁽³⁾
Common Stock	08/06/2010		C⁽²⁾		498,394⁽³⁾	A	⁽²⁾	1,560,254⁽³⁾	I	Shares are held directly by KPCB Pandemic and Bio Defense Fund, LLC⁽³⁾
Common Stock	08/06/2010		C⁽²⁾		2,965⁽³⁾	A	⁽²⁾	1,563,219⁽³⁾	I	Shares are held directly by KPCB PBD Founders Fund, LLC⁽³⁾
Common Stock	08/06/2010		P		823,906⁽³⁾	A	$5	2,387,125⁽³⁾	I	Shares are held directly by KPCB Pandemic and Bio Defense Fund, LLC⁽³⁾
Common Stock	08/06/2010		P		4,901⁽³⁾	A	$5	2,392,026⁽³⁾	I	Shares are held directly by KPCB PBD Founders Fund, LLC⁽³⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Series B Preferred Stock	⁽¹⁾	08/06/2010		C			9,078,000	⁽¹⁾	⁽¹⁾	Common Stock	1,055,581	$0.00	0	I	Shares held directly by KPCB Pandemic and Bio Defense Fund, LLC⁽³⁾
Series B Preferred Stock	⁽¹⁾	08/06/2010		C			54,000	⁽¹⁾	⁽¹⁾	Common Stock	6,279	$0.00	0	I	Shares held directly by KPCB PBD Founders Fund, LLC⁽³⁾
8% Convertible Promissory Note	⁽²⁾	08/06/2010		C			498,394	⁽²⁾	⁽²⁾	Common Stock	498,394	$0.00	0	I	Shares held directly by KPCB Pandemic and Bio Defense Fund, LLC⁽³⁾
8% Convertible Promissory Note	⁽²⁾	08/06/2010		C			2,965	⁽²⁾	⁽²⁾	Common Stock	2,965	$0.00	0	I	Shares held directly by KPCB PBD Founders Fund, LLC⁽³⁾

Explanation of Responses:

1. Series B Preferred Stock was converted into shares of the Issuers Common Stock upon the consummation on the Issuer's initial Public Offering on an 8.6 for 1 basis.

2. Principal and accrued interest was converted upon the Issuer's initial public offering into shares of Common Stock at a conversion price of 87.5% of the per share price of the Common Stock sold in the Issuer's initial public offering on August 6, 2010, at $5.00 per share.

3. The Reporting Person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

	/s/ Theodore E. Schlein, Manager of KPCB PBD Associates, LLC, Manager of the Reporting Person	08/06/2010
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.